| Trial ID: | L6887 |
| Source ID: | NCT00651105
|
| Associated Drug: |
Vildagliptin
|
| Title: |
Effect of LAF237 on Glucagon Secretion in Patients With Type 2 Diabetes and in Healthy Subjects
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type-2 Diabetes|Healthy
|
| Interventions: |
DRUG: Vildagliptin|DRUG: Placebo
|
| Outcome Measures: |
Primary: GLP-1 and non GLP-1 effects of LAF237 on glucagon secretion in patients with Type-2 diabetes and matching healthy subjects, from baseline to Day 10 | Secondary: Effects of LAF237 on prandial glucose profiles, prandial insulin, and gastric-emptying in patients with Type-2 diabetes and in matching healthy subjects., 10 day treatment periods
|
| Sponsor/Collaborators: |
Sponsor: Novartis
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
63
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2008-02
|
| Completion Date: |
|
| Results First Posted: |
|
| Last Update Posted: |
2016-11-18
|
| Locations: |
Novartis Investigator Site, Bad Lauterberg im Harz, Germany|Novartis Investigator Site, Berlin, Germany
|
| URL: |
https://clinicaltrials.gov/show/NCT00651105
|
